Monogram Orthopaedics Inc (MGRM) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -100.00%
• EPS Growth: -43.67%
• Country: US
• Employees: N/A
• Sector: N/A
• Sector Strength: N/A
• Industry: N/A
• EPS (TTM): N/A
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ―

Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock's upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.

Monogram Orthopaedics Inc Business Overview & Revenue Model

Company Description

Monogram Orthopaedics Inc (MGRM) is a medical technology company that specializes in the development and commercialization of innovative orthopedic solutions. The company operates in the healthcare sector, focusing on advanced surgical technologies and personalized implants, primarily for joint replacement surgeries. Monogram Orthopaedics leverages robotic systems and 3D printing to produce customized implants aimed at improving surgical outcomes and patient recovery times.

How the Company Makes Money

Monogram Orthopaedics Inc generates revenue primarily through the sale of its orthopedic implants and associated surgical systems. The company's revenue model is based on direct sales to healthcare providers, hospitals, and surgical centers. Additionally, Monogram may engage in partnerships with other medical device companies to expand its market reach and enhance its product offerings. Revenue can also be derived from licensing its proprietary technology to other entities in the medical field. The company's earnings are influenced by its ability to innovate and bring cutting-edge solutions to market, as well as its capacity to establish relationships with key stakeholders in the healthcare industry.

Monogram Orthopaedics Inc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Monogram Orthopaedics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: ―
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGRM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 5.86, equal to the 50-day MA of 5.67, and equal to the 200-day MA of 3.59, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 62.71 is Neutral, neither overbought nor oversold. The STOCH value of 71.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGRM.

Monogram Orthopaedics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―

Monogram Orthopaedics Inc Corporate Events

Monogram Orthopaedics Gains Approval for Indian Clinical Trials

On April 29, 2025, Monogram Technologies Inc. announced it received regulatory approval from India’s Central Drugs Standard Control Organization to conduct clinical trials for its mBôs TKA system. This approval marks a significant milestone for Monogram, as it collaborates with Shalby Hospitals to evaluate the safety and effectiveness of its system in a 102-patient trial. The initiative is expected to enhance Monogram’s industry positioning by demonstrating the system’s performance in real surgical settings, potentially advancing orthopedic innovation globally.

Spark’s Take on MGRM Stock

According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.

Monogram Orthopaedics Inc. has strengths in recent FDA approval and technological advancements, which are key positive drivers. However, financial instability, regulatory uncertainties, and negative profitability weigh heavily on the overall score. While technical indicators show upward momentum, the high RSI indicates potential risk of a pullback. Valuation metrics are weak due to the lack of profitability and dividends.

To see Spark’s full report on MGRM stock, click here.

Monogram Orthopaedics Gains FDA Clearance for TKA System

On March 17, 2025, Monogram Technologies Inc. announced that it received FDA 510(k) clearance for its Monogram mBôs™ TKA System, allowing it to market the device under specific regulatory provisions. This clearance marks a significant milestone for the company, highlighting years of innovation and teamwork in advancing orthopedic robotics. The system is designed to enhance safety, efficiency, and accuracy in robotic-assisted total knee arthroplasty and is positioned for future expansion into other orthopedic applications. The company is preparing for commercialization and aims to establish clinical experience with key surgeons to demonstrate the system’s advantages. This development opens new domestic and international opportunities, supporting Monogram’s strategic growth and long-term commercialization strategy.

Monogram Orthopaedics Awaits FDA Clearance for mBôs TKA System

On February 25, 2025, Monogram Technologies Inc. announced the completion of supplemental testing and submission of a formal response to the FDA’s Additional Information Request for its mBôs TKA System. The company anticipates a favorable clearance decision, which would allow commercialization in the U.S. Monogram also held an Investigator Meeting in India as part of a collaboration with Shalby Limited and Reliance Life Sciences to prepare for a clinical trial of the mBôs TKA System. The company has made significant advancements in its robotic system, enhancing cutting speeds and maintaining accuracy, positioning it as a competitive solution in the orthopedic robotics market.